Видео ютуба по тегу Adverse Risk Mutations

Impact of ASXL1 mutations in favorable risk AML treated with ven-containing low-intensity therapy
Impact of ASXL1 mutations in favorable risk AML treated with ven-containing low-intensity therapy
Identifying low- and high-risk AML
Identifying low- and high-risk AML
Risk factors for progression in MPNs
Risk factors for progression in MPNs
The impact of cytogenetic-risk stratification on AML outcomes
The impact of cytogenetic-risk stratification on AML outcomes
Molecular Mutations in AML and MDS: Adverse Impact of TET2
Molecular Mutations in AML and MDS: Adverse Impact of TET2
Classification of high-risk mutations in MDS
Classification of high-risk mutations in MDS
Impact of high-risk mutations on outcomes of patients with AML receiving CPX-351 induction
Impact of high-risk mutations on outcomes of patients with AML receiving CPX-351 induction
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
Validation of adverse risk subgroups in patients with AML undergoing alloSCT
Validation of adverse risk subgroups in patients with AML undergoing alloSCT
AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
Могу ли я находиться в группе высокого риска при отрицательной генетике? Маккензи Смартт, магистр...
Могу ли я находиться в группе высокого риска при отрицательной генетике? Маккензи Смартт, магистр...
Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML
Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML
Which gene mutations are categorized as low, intermediate and high risk AML? #AML
Which gene mutations are categorized as low, intermediate and high risk AML? #AML
2021 FORCE | Hereditary Cancer | Cancer Risks, Screening & Prevention for BRCA1 or BRCA2 Mutations
2021 FORCE | Hereditary Cancer | Cancer Risks, Screening & Prevention for BRCA1 or BRCA2 Mutations
How Do Genetic Mutations Impact Breast Cancer Risk, Prognosis and Treatment?
How Do Genetic Mutations Impact Breast Cancer Risk, Prognosis and Treatment?
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
Mutation-based Risk Stratification Approaches in Myelofibrosis: Any Real Clinical Utility?
Mutation-based Risk Stratification Approaches in Myelofibrosis: Any Real Clinical Utility?
Are gene mutations good or bad?
Are gene mutations good or bad?
Мутации BRCA1 и BRCA2 и рак (типы рака и кто подвержен наибольшему риску)
Мутации BRCA1 и BRCA2 и рак (типы рака и кто подвержен наибольшему риску)
Mutations (Updated)
Mutations (Updated)
There's another gene mutation that increases risk of developing breast cancer
There's another gene mutation that increases risk of developing breast cancer
Case 4: Risk Factors and Genetic Abnormalities of MPN
Case 4: Risk Factors and Genetic Abnormalities of MPN
The impact of secondary-type mutations in NPM1-mutated AML
The impact of secondary-type mutations in NPM1-mutated AML
A mutation in BARD1 can increase the risk for breast cancer. Early screening and regu...
A mutation in BARD1 can increase the risk for breast cancer. Early screening and regu...